Canada · 
What does GeneChem invest in?
GeneChem invests most often at Series B and Series A (67% of the rounds on record), in sectors such as E-Commerce, Energy and Health Care.
GeneChem highlights
- 01
21 rounds on record
- 02
Mostly Series B and Series A: 67% of its rounds
- 03
6 exits from the portfolio
What they do
- Type
- Growth equity (from a list, unverified)
- Cheque size
- Not stated
- Sectors
- E-CommerceEnergyHealth Care
- Based in
- Montreal, Canada
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first21 appearances
- 2014
1 round
- May
- 2013
1 round
- Jun
- 2012
3 rounds
- Nov
- Aug
- Jan
- 2011
3 rounds
- Jun
- Apr
- Feb
- 2010
3 rounds
- Sept
- Sept
- Feb
- 2008
2 rounds
- Sept
- Jan
- 2007
3 rounds
- Nov
- Jan
- Jan
- 2006
1 round
- Dec
- 2005
1 round
- May
- 2003
2 rounds
- Dec
- Jul
- 2001
1 round
- Jul
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
We hold 4 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
Exits from the portfolio
Companies it backed that were later bought or listed6 in all
Ambit BiosciencesBought by Daiichi Sankyo$410MSept 2014
Conatus PharmaceuticalsListed$69MJun 2013
CytochromaBought by OPKO HealthUndisclosedJan 2013
Xanthus PharmaceuticalsBought by AntisomaUndisclosedMay 2008
LymphoSignBought by Aegera TherapeuticsUndisclosedAug 2007
NewBioticsBought by Celmed BiosciencesUndisclosedJul 2004
An exit counts when it came after the firm's first round in the company. From historical deal records.